with type 2 diabetes failing oral agent therapy causes a marked reduction inHbA 1c. Acknowledgments — This study was funded by Amylin Pharmaceuticals, Inc. We thank Dr.Loretta Nielsen for manuscript revisions. References 1. American Diabetes Association: Postpran- dial blood glucose. Diabetes Care 24:775– 778, 2001 2. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secre-tory dysfunction and insulin resistance inthe pathogenesis of type 2 diabetes melli-tus.J Clin Invest 104:787–794, 1999 3. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 16: over-view of 6 years’ therapy of type II diabetes:a progressive disease. Diabetes 44:1249– 1258, 1995 4. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sul-phonylureas or insulin compared withconventional treatment and risk of com-plications in subjects with type 2 diabetes(UKPDS 33). Lancet 352:837–853, 1998 5. Mudaliar S, Edelman SV: Insulin therapy